For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .
On-demand IC351 (Cialis™) enhances erectile function in patients with erectile dysfunction
IC351 ( Cialis ™ ) is a selective inhibitor of PDE5 . The efficacy and safety of on-dem and dosing of IC351 in men with erectile dysfunction was assessed in a multicenter , double-blind , placebo-controlled study . One hundred seventy-nine men ( mean age : 56 y ) were r and omized to receive placebo or IC351 at doses of 2 , 5 , 10 or 25 mg , taken on dem and over a 3-week period . The primary endpoints were change from baseline in responses to Questions 3 ( Q3 ) and 4 ( Q4 ) of the International Index of Erectile Function ( IIEF ) . IC351 significantly improved IIEF Q3 scores at all doses vs placebo ( P≤0.003 ) . IC351 also significantly improved IIEF Q4 scores in all but the 2 mg group ( P≤0.0003 ) . No significant changes in laboratory values , ECGs , or blood pressure were observed . The most common adverse events were headache and dyspepsia . The conclusion of this study was that on-dem and IC351 at doses up to 25 mg was well tolerated and significantly improved erectile function
For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .